Insilico Medicine, Inc. has entered into a research collaboration with Pfizer Inc. to utilize Insilico's machine learning technology and proprietary Pandomics Discovery Platform with the aim of identifying real-world evidence for potential therapeutic targets implicated in a variety of diseases.